Acute and Chronic Renal Failure

Published on 06/06/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1913 times

65 Acute and Chronic Renal Failure

Acute Renal Failure

Acute kidney injury (AKI), previously referred to as acute renal failure (ARF), is defined as an abrupt reduction in kidney function measured by a rapid decline in glomerular filtration rate (GFR). AKI implies that an acute decline in kidney function is secondary to an injury that leads to functional or structural changes in the kidney. AKI is characterized by a disturbance of renal physiologic functions, including impairment of nitrogenous waste product excretion and inability to regulate water, electrolyte, and acid–base homeostasis. The precise incidence and prevalence of AKI in children is difficult to ascertain. The overall incidence of AKI appears to be rising because of advances in pediatric medical technology including bone marrow, hepatic, and cardiac transplantation, in surgery for congenital heart disease, and in the care of very low birth weight infants.

Etiology and Pathogenesis

The causes of AKI can be related to any process that interferes with the structure or function of the renal vasculature, glomeruli, renal tubules, interstitium, or urinary tract. The causes of AKI can be categorized as prerenal, renal (intrinsic renal disorder), or postrenal.

Renal

AKI (intrinsic renal disease) is the result of disorders that involve the renal vascular, glomerular, or tubular–interstitial pathology. Acute tubular necrosis (ATN) results from ischemia caused by decreased renal perfusion or injury from tubular nephrotoxins (Figure 65-1). All causes of prerenal AKI can progress to ATN if renal perfusion is not restored or nephrotoxins are not withdrawn. Nephrotoxic AKI is mostly caused by toxic tubular injury by medications, including aminoglycosides, contrast agents, amphotericin B, chemotherapeutic agents (ifosfamide, cisplatin), and acyclovir. Toxic tubular injury can also be induced by the release of heme pigments, as it occurs from myoglobinuria caused by rhabdomyolysis and hemoglobinuria caused by intravascular hemolysis. Uric acid nephropathy and tumor lysis syndrome are causes of AKI in children with leukemia. During chemotherapy, a rapid breakdown of tumor cells causes increased release and subsequent excretion of uric acid, resulting in precipitation of uric acid crystals in the tubules and renal microvasculature. Hyperphosphatemia in tumor lysis syndrome results in precipitation of calcium phosphate crystals in the tubules. Acute interstitial nephritis most commonly results from hypersensitivity reactions to drugs, including penicillin analogs (e.g., methicillin), cimetidine, sulfonamides, rifampin, nonsteroidal antiinflammatory drugs, and proton pump inhibitors, but can also be idiopathic. Glomerulonephritis of any etiology (including those caused by vasculitis, systemic lupus erythematosus, or Goodpasture’s syndrome) may present with AKI, with postinfectious glomerulonephritis being the most common cause of AKI in this group. Rapidly progressive glomerulonephritis presents as the most severe degree of any form of glomerulonephritis and presents with AKI. Vascular causes of AKI include cortical necrosis (mostly caused by hypoxic or ischemic injury in newborns), renal artery or vein thrombosis, and hemolytic-uremic syndrome (HUS).

Clinical Presentation

A careful history and physical examination can frequently identify disease processes that underlie AKI and suggest an underlying diagnosis.

Evaluation and Diagnosis

In addition to a careful history and physical examination, the initial evaluation includes additional laboratory studies.

Prevention and Management

The basic principles of the general management of AKI are shown in Box 65-1.

General measures to help prevent AKI include close monitoring of serum levels of nephrotoxic drugs, adequate fluid repletion in patients with hypovolemia, and aggressive hydration and alkalinization of the urine before chemotherapy. Unless contraindicated, a child with a history of fluid loss (vomiting and diarrhea), a physical examination consistent with hypovolemia (hypotension and tachycardia), or oliguria requires immediate intravenous (IV) fluid therapy in an attempt to restore renal function and perhaps prevent ischemic renal injury. Commonly used fluids are crystalloid solutions, such as normal saline (20 mL/kg) administered over 20 to 30 minutes, which may be repeated. If urine output does not increase and renal function fails to improve, invasive monitoring may be required to adequately assess the child’s fluid status and help guide further therapy.

Hyperkalemia is a life-threatening complication of AKI that may result in fatal cardiac arrhythmia. Hyperkalemia is treated by shifting potassium from the intravascular to the intracellular space using IV glucose and insulin, β-agonists (albuterol inhalation), and bicarbonate and by using enteric exchange resins such as polystyrene sulfonate. IV infusion of calcium is used to stabilize cell membranes and decrease the risk of cardiac arrhythmias. Dialysis may be required to remove potassium.

Acid (H+) generated by diet and intermediary metabolism is excreted by the kidney, but in AKI, acid excretion is decreased, resulting in metabolic acidosis. Acidosis can be treated with IV or oral sodium bicarbonate or oral sodium citrate solutions.

Chronic Kidney Disease

Chronic kidney disease (CKD) is a state of irreversible kidney damage or reduction of kidney function that can lead to a progressive decrease in kidney function. CKD more clearly defines renal dysfunction as a continuum rather than a discrete change in renal function. The term CKD replaces the clinical terms of chronic renal failure and chronic renal insufficiency. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) has defined CKD as (1) the presence of markers of kidney damage for 3 months or longer, as defined by structural or functional abnormalities of the kidney with or without a decreased GFR, which is manifested by either pathologic abnormalities or other markers of kidney damage, including abnormalities in the blood, urine, or in imaging tests, or (2) GFR below 60 mL/min/1.73 m2 for 3 months or longer with or without kidney damage. GFR is estimated by creatinine clearance.

The stages of CKD for children older than 2 years of age are based on estimated GFR (using the Schwartz equation) and are aimed at promoting early detection and treatment of CKD.

The annual incidence and prevalence of CKD, including its early stages, is reported as 12.1 per million children and adolescents younger than 20 years. The yearly incidence and prevalence in stages 4 and 5 is reported as 5.7 to 14.8 per million children in different countries. The variability in the worldwide incidence of CKD is thought to be affected by genetic and environmental factors, as well as the ability to detect CKD and provide care to children with significant renal impairment. In North America, the incidence of CKD is greater in African American than white children. The incidence and prevalence of CKD are greater in boys than girls because of the higher incidence of congenital anomalies of the kidney and urinary tract, including obstructive uropathy, renal dysplasia, renal hypoplasia, and prune belly syndrome, in boys.

Etiology and Pathogenesis

Based on the registry of the North American Pediatric Renal Trials and Collaborative Studies, the causes of CKD are as follows: Congenital renal anomalies are present in 57% of cases (obstructive uropathy; renal aplasia, hypoplasia, or dysplasia; reflux nephropathy; and polycystic kidney disease), and glomerular disease is present in 17% of cases, with focal segmental glomerulosclerosis (FSGS) being the most common glomerular disorder (9% of all CKD cases; African American children are three times more likely to develop FSGS than white children). Other causes accounted for 25% of cases and included HUS, genetic disorders (e.g., cystinosis, oxalosis, hereditary nephritis), and interstitial nephritis. In large number of cases (18%), the primary disease is unknown because patients present in late stages of CKD. Unlike in adults, diabetic nephropathy and hypertension are rare causes of CKD in children (Figure 65-2).

After initial injury to the kidney, there is continued progression of renal disease and functional impairment, often leading to stage 5 CKD. This is a result of repeated and chronic insults to the renal parenchyma, leading to permanent damage or to the adaptive hyperfiltration response of the remaining nephrons in the kidney, which compensates for the loss of nephrons from the initial injury. Over time, the enhanced transglomerular ultrafiltration and glomerular pressure leads to glomerular damage and leakage of protein, resulting in interstitial inflammation and fibrosis. This long-term injury is characterized histologically by glomerulosclerosis, vascular sclerosis, and tubulointerstitial fibrosis and clinically by proteinuria and progressive renal insufficiency. The rate of progression of CKD is usually greatest during the two periods of rapid growth, infancy and puberty, when the sudden increase in body mass results in an increase in the filtration demands of the remaining nephrons. Other factors associated with acceleration of the progressive CKD include hypertension, obesity, dyslipidemia, proteinuria, anemia, intrarenal precipitation of calcium and phosphate, metabolic acidosis, and tubular interstitial disease. Some of these factors are modifiable, and timely therapeutic interventions may result in a reduced rate of deterioration of renal function.

Clinical Presentation

Clinical presentation of CKD depends on the severity of renal disease and the underlying disorder. Stage 1 and 2 CKD are usually asymptomatic. As CKD progresses, patients become increasingly symptomatic. Signs and symptoms of CKD include different amounts of urine output (polyuria or oliguria), edema, hypertension, proteinuria, and hematuria. Glomerular diseases often present with hematuria, proteinuria, hypertension, and edema in the early stages of CKD. Polyuria may be an early presenting symptom as congenital anomalies of the kidney and urinary tract (e.g., obstructive uropathy); inherited disorders (e.g., nephronophthisis); and tubulointerstitial disorders caused by impairment in renal concentrating ability, which generally precedes a significant reduction in GFR. Poor growth is a common manifestation of CKD in children. More severe symptoms and signs of CKD begin to appear with stage 3 disease and worsen with stages 4 and 5.

Complications

A moderate to severe loss of GFR (stage 3-5 disease) is associated with a number of complications caused by impairment of many renal functions, resulting in disorders of fluid and electrolytes, acid–base homeostasis, metabolic bone disease, anemia, hypertension, dyslipidemia, endocrine abnormalities, and growth retardation.

Abnormalities in mineral metabolism and bone structure are common findings in stage 3 CKD (Figure 65-3). There is retention of phosphate because of decreased GFR and decreased renal production of 1,25-dihydroxy vitamin D. This leads to decreased serum calcium levels and subsequent elevation of serum parathyroid hormone (PTH). This secondary hyperparathyroidism results in reabsorption of calcium from bone, leading to bone disease that presents with difficulty in walking, bone pain, skeletal deformities, and fractures.
Uremia represents a constellation of symptoms and signs present in the final stage of CKD (Figure 65-4). These include anorexia, nausea, vomiting, growth retardation, platelet dysfunction (abnormal platelet adhesion and aggregation), pericardial disease (pericarditis and pericardial effusion), neurologic abnormalities (peripheral neuropathy, lethargy, seizures, coma, and death), and altered cognitive development (loss of concentration, poor school performance, and mental retardation).

Evaluation

Laboratory Testing

There is no single pattern of laboratory abnormalities that characterizes pediatric CKD, but some abnormalities are commonly present and are indicative of underlying chronic kidney dysfunction. Serum creatinine is the most commonly used test to estimate the GFR (creatinine clearance indirectly represents the GFR) using the Schwartz formula: GFR = kL/SCr, where k is a constant that varies with age and sex, L is length (cm), and SCr is serum creatinine in mg/dL (Table 65-1). The GFR is then used to determine the stage of CKD. Normal levels of GFR vary with age, gender, and body size (Table 65-2). GFR increases with maturation from infancy and approaches adult mean value by 2 years of age.

Table 65-1 Stages of Chronic Kidney Disease for Children Older Than 2 Years of Age

Stage Glomerular Filtration Rate
1 Normal (≥90 mL/min/1.73 m2)
2 60-89 mL/min/1.73 m2
3 30-59 mL/min/1.73 m2
4 15-29 mL/min/1.73 m2
5 <15 mL/min/1.73 m2 or ESRD

ESRD, end-stage renal disease.

Table 65-2 Normal Glomerular Filtration Rate Levels and the Schwartz Equation

Age (Gender) Schwartz Equation (Serum Creatinine in mg/dL, Length in cm) Mean GFR ± SD (mL/min/1.73m2)
1 wk (boys and girls) GFR = 0.33*(Length/SCr) in preterm infants 40.6 ± 14.8
GFR = 0.45*(Length/SCr) in term infants
2-8 wk (boys and girls) GFR = 0.45*(Length/SCr) 65.8 ± 24.8
>8 wk (boys and girls) GFR = 0.45*(Length/SCr) 95.7 ± 21.7
2-12 y (boys and girls) GFR = 0.55*(Length/SCr) 133.0 ± 27.0
13-18 y (boys) GFR = 0.70*(Length/SCr) 140.0 ± 30.0
13-18 y (girls) GFR = 0.55*(Length/SCr) 126.0 ± 22.0

GFR, glomerular filtration rate; SCr, serum creatinine; SD, standard deviation.

Electrolytes are tested to evaluate for hyperkalemia and metabolic acidosis. Serum calcium, phosphorus, and PTH level are needed to detect abnormalities in bone mineral metabolism. Lipid profile is needed to detect dyslipidemia. A complete blood count will detect anemia, and RBC indices will characterize the anemia and help eliminate other causes of anemia other than CKD, determining the iron profile (serum iron, total iron-binding capacity, percent transferrin saturation) and looking for possible blood losses (test for occult blood) is necessary.

Management

The general management of a patient with CKD includes the following components: treatment of reversible renal dysfunction (some renal function may be recovered if treatment is initiated early), prevention of progression of renal disease, treatment of complications, and identification of renal replacement therapy.

Management of Complications

Sodium and water retention occur as GFR becomes severely decreased in stages 4 and 5 CKD. This is treated with dietary sodium restriction and diuretics. Some children with obstructive uropathy or renal dysplasia have a poor urinary concentrating capacity and sodium wasting, making them prone to hypovolemia and hyponatremia.

Renal Replacement Therapy

Renal replacement therapy is achieved by PD, HD, and kidney transplantation. Renal replacement therapy is generally needed with GFR less than 15 mL/min/1.73 m2 (stage 5 CKD). However, renal replacement therapy in children may be initiated sooner if there is poor calorie intake resulting in failure to thrive, symptomatic uremia (e.g., pericarditis), and significant delay in psychomotor and cognitive development. The choice among renal replacement options is dictated by family preference and technical, psychosocial and compliance issues.

PD is more common in infants and younger children largely because of problems of vascular access in that age group (Figure 65-5). A PD catheter is surgically placed into the peritoneal space. PD fluid is pumped into the peritoneal space. Peritoneal membrane serves as a “filter” through which waste products and water are cleared from blood that circulates through blood vessels of the peritoneal membrane. Waste products and water are transferred to the PD fluid in the peritoneal space by processes of diffusion and osmosis. This fluid is then drained out of the peritoneal space. PD can be performed by parents at home, overnight with a cycling machine that allows the least disruption of home life, school, and work attendance.
HD is more commonly used in older children (Figure 65-6). HD requires vascular access such as placement of an arteriovenous fistula, arteriovenous graft, or central venous catheter. Blood is pumped from the vascular access into the dialyzer, which contains an artificial membrane that serves as a filter through which waste products and water are cleared from the blood into the dialysis fluid by processes of diffusion, convection, and ultrafiltration. Dialysis fluid flows through the dialyzer countercurrent to the blood. HD is done in specialized HD centers using a HD machine and requires at least three weekly treatments that are each 3 to 5 hours long.

Suggested Readings

Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028-1035.

Andreoli SP. Acute kidney injury in children. Pediatr Nephrol. 2009;24(2):253-263.

Andreoli SP. Management of acute kidney injury in children: a guide for pediatricians. Paediatr Drugs. 2008;10(6):379-390.

Benfield MR, Bunchman TE. Management of acute renal failure. In: Avner ED, Harmon WE, Niaudet P, editors. Pediatric Nephrology. Philadelphia, Lippincott: Williams & Wilkins; 2004:1253-1266.

Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353.

Fine RN, Whyte DA, Boydstun II. Conservative management of chronic renal insufficiency. In: Avner ED, Harmon WE, Niaudet P, editors. Pediatric Nephrology. Philadelphia, Lippincott: Williams & Wilkins; 2004:1253-1266.

Greenbaum LA. Anemia in children with chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(4):385-396.

Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol. 2008;23(3):363-371.

Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2008;23(12):2151-2157.

Srivastava T, Warady BA: Overview of the management of chronic kidney disease in children, UpToDate 17.1, 2009.

Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol. 2008;23(2):195-207.

Wong CS, Warady BA: Epidemiology, etiology, and course of chronic kidney disease in children. UpToDate 17.1, 2009.

Wong CS, Warady BA, Srivastava T: Clinical presentation and evaluation of chronic kidney disease in children. UpToDate 17.1, 2009.